At the time of writing, Aquestive Therapeutics Inc [AQST] stock is trading at $5.16, up 5.74%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AQST shares have gain 8.98% over the last week, with a monthly amount drifted -8.83%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Aquestive Therapeutics Inc [NASDAQ: AQST] stock has seen the most recent analyst activity on May 10, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $8. Previously, Piper Sandler started tracking the stock with Overweight rating on April 11, 2024, and set its price target to $10. On March 28, 2024, Raymond James initiated with a Outperform rating and assigned a price target of $7 on the stock. H.C. Wainwright initiated its recommendation with a Buy. Lake Street started tracking with a Buy rating for this stock on January 03, 2019, and assigned it a price target of $14. In a note dated August 20, 2018, RBC Capital Mkts initiated an Outperform rating and provided a target price of $23 on this stock.
For the past year, the stock price of Aquestive Therapeutics Inc fluctuated between $1.84 and $6.23. Currently, Wall Street analysts expect the stock to reach $10.25 within the next 12 months. Aquestive Therapeutics Inc [NASDAQ: AQST] shares were valued at $5.16 at the most recent close of the market. An investor can expect a potential return of 98.64% based on the average AQST price forecast.
Analyzing the AQST fundamentals
According to Aquestive Therapeutics Inc [NASDAQ:AQST], the company’s sales were 58.90M for trailing twelve months, which represents an 4.15% jump. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.36%, Pretax Profit Margin comes in at -0.6%, and Net Profit Margin reading is -0.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 0.63 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.97 points at the first support level, and at 4.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.27, and for the 2nd resistance point, it is at 5.39.
Ratios To Look Out For
It is important to note that Aquestive Therapeutics Inc [NASDAQ:AQST] has a current ratio of 6.37. In addition, the Quick Ratio stands at 5.91 and the Cash Ratio stands at 5.14. Considering the valuation of this stock, the price to sales ratio is 8.45.
Transactions by insiders
Recent insider trading involved Jung Cassie, Chief Operating Officer, that happened on Nov 26 ’24 when 44.0 shares were sold. Chief Innovation/Tech Officer, Schobel Alexander Mark completed a deal on Mar 15 ’24 to sell 50000.0 shares. Meanwhile, Chief Innovation/Tech Officer Schobel Alexander Mark sold 25000.0 shares on Mar 08 ’24.
